Comments
Natco Pharma Ltd said consolidated net profit had declined 39.4 per cent at ₹63.40 crore in the third quarter ended December 31, 2020 against ₹104 crore in the corresponding quarter of the previous financial year.
The total revenue of the Hyderabad-based company declined 24.7 per cent at ₹386 crore compared to ₹513 crore in the same period last year.
Also read: Natco Pharma expects agri business to be key growth lever
“The decline in revenue and profits was due to lower sales in domestic oncology and weak realisation of profits from Oseltamivir in the USA,” the company said in a release issued on Thursday.
The board of directors has recommended a third interim dividend of ₹1 per equity share of face value ₹2 each.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.